A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia

被引：2

作者：

Parrondo, Ricardo D. ^{[1
]}

Dutta, Navnita ^{[2
]}

Laplant, Betsy R. ^{[3
]}

Elliott, Jamie ^{[1
]}

Fernandez, Andre ^{[1
]}

Zimmerman, Ashley ^{[1
]}

Cicco, Gina ^{[2
]}

Han, Bing ^{[2
]}

Heslop, Keisha ^{[1
]}

Chapin, Dustin ^{[1
]}

Sher, Taimur ^{[1
]}

Roy, Vivek ^{[1
]}

Rasheed, Ahsan ^{[1
]}

Das, Saurav ^{[1
]}

Chanan-Khan, Asher A. ^{[1
,2
]}

Paulus, Aneel ^{[2
]}

Ailawadhi, Sikander ^{[1
,2
,4
]}

机构：

[1] Mayo Clin, Canc Ctr, Jacksonville, FL USA

[2] Mayo Clin, Dept Canc Biol, Jacksonville, FL USA

[3] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA

[4] Mayo Clin, Div Hematol Oncol, 4500 San Pablo Rd, Mangurian Bldg 3rd Floor, Jacksonville, FL 32224 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 204卷 / 05期

关键词：

clinical trials; non Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia; WALDENSTROM MACROGLOBULINEMIA; RITUXIMAB; DEXAMETHASONE; ZANUBRUTINIB; THERAPY;

D O I：

10.1111/bjh.19320

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This phase II study evaluated time-limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenstrom macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable patients with no patient achieving a complete response (CR). The median duration of treatment was 15.6 months, and after a median follow-up time of 25.7 months, the median progression-free survival (PFS) was 22.9 months. While the primary end-point was not met (CR rate at any time) and 28.5% discontinued treatment due to toxicity, ibrutinib plus ixazomib led to a clinically meaningful ORR and PFS. Combined Bruton's tyrosine kinase (BTK) and proteasome inhibition merits further evaluation in WM.

引用

页码：1825 / 1829

页数：5

共 50 条

[21] All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study [J].

Touzeau, Cyrille ;

Perrot, Aurore ;

Roussel, Murielle ;

Karlin, Lionel ;

Benboubker, Lotfi ;

Jacquet, Caroline ;

Mohty, Mohamad ;

Facon, Thierry ;

Manier, Salomon ;

Chretien, Marie-Lorraine ;

Tiab, Mourad ;

Hulin, Cyrille ;

Leleu, Xavier ;

Loiseau, Herve Avet ;

Dejoie, Thomas ;

Planche, Lucie ;

Attal, Michel ;

Moreau, Philippe .

HAEMATOLOGICA, 2022, 107 (07) :1693-1697

[22] Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study [J].

Tanaka, Maki ;

Takamatsu, Yasushi ;

Anan, Keisei ;

Ohno, Shinji ;

Nishimura, Reiki ;

Yamamoto, Yutaka ;

Masuda, Norikazu ;

Mitsuyama, Shoshu ;

Tamura, Kazuo .

ANTI-CANCER DRUGS, 2010, 21 (04) :453-458

[23] A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy [J].

Finazzi, Guido ;

Vannucchi, Alessandro M. ;

Martinelli, Vincenzo ;

Ruggeri, Marco ;

Nobile, Francesco ;

Specchia, Giorgina ;

Pogliani, Enrico Maria ;

Olimpieri, Odoardo Maria ;

Fioritoni, Giuseppe ;

Musolino, Caterina ;

Cilloni, Daniela ;

Sivera, Piera ;

Barosi, Giovanni ;

Finazzi, Maria Chiara ;

Di Tollo, Silvia ;

Demuth, Tim ;

Barbui, Tiziano ;

Rambaldi, Alessandro .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (05) :688-694

[24] A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases [J].

Leone, Jose Pablo ;

Duda, Dan G. ;

Hu, Jiani ;

Barry, William T. ;

Trippa, Lorenzo ;

Gerstner, Elizabeth R. ;

Jain, Rakesh K. ;

Tan, Sally ;

Lawler, Elizabeth ;

Winer, Eric P. ;

Lin, Nancy U. ;

Tolaney, Sara M. .

BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) :113-123

[25] Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma [J].

Berdeja, Jesus G. ;

Hart, Lowell L. ;

Mace, Joseph R. ;

Arrowsmith, Edward R. ;

Essell, James H. ;

Owera, Rami S. ;

Hainsworth, John D. ;

Flinn, Ian W. .

HAEMATOLOGICA, 2015, 100 (05) :670-676

[26] A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients [J].

Laquente, Berta ;

Lopez-Martin, Jose ;

Richards, Donald ;

Illerhaus, Gerald ;

Chang, David Z. ;

Kim, George ;

Stella, Philip ;

Richel, Dirk ;

Szcylik, Cezary ;

Cascinu, Stefano ;

Frassineti, G. L. ;

Ciuleanu, Tudor ;

Hurt, Karla ;

Hynes, Scott ;

Lin, Ji ;

Lin, Aimee Bence ;

Von Hoff, Daniel ;

Calvo, Emiliano .

BMC CANCER, 2017, 17

[27] Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study [J].

Tempero, M. ;

Oh, D-Y ;

Tabernero, J. ;

Reni, M. ;

Van Cutsem, E. ;

Hendifar, A. ;

Waldschmidt, D-T ;

Starling, N. ;

Bachet, J-B ;

Chang, H-M ;

Maurel, J. ;

Garcia-Carbonero, R. ;

Lonardi, S. ;

Coussens, L. M. ;

Fong, L. ;

Tsao, L. C. ;

Cole, G., Jr. ;

James, D. ;

Macarulla, T. .

ANNALS OF ONCOLOGY, 2021, 32 (05) :600-608

[28] A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen [J].

Daniely, David ;

Forouzan, Eli ;

Spektor, Tanya M. ;

Cohen, Alexa ;

Bitran, Jacob D. ;

Chen, Gigi ;

Moezi, Mehdi M. ;

Bessudo, Alberto ;

Hrom, John ;

Eshaghian, Shahrooz ;

Swift, Regina A. ;

Eades, Benjamin M. ;

Kim, Clara ;

Lim, Stephen ;

Berenson, James R. .

EXPERIMENTAL HEMATOLOGY, 2022, 111 :79-86

[29] Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study [J].

Gopal, Ajay K. ;

Schuster, Stephen J. ;

Fowler, Nathan H. ;

Trotman, Judith ;

Hess, Georg ;

Hou, Jing-Zhou ;

Yacoub, Abdulraheem ;

Lill, Michael ;

Martin, Peter ;

Vitolo, Umberto ;

Spencer, Andrew ;

Radford, John ;

Jurczak, Wojciech ;

Morton, James ;

Caballero, Dolores ;

Deshpande, Sanjay ;

Gartenberg, Gary J. ;

Wang, Shean-Sheng ;

Damle, Rajendra N. ;

Schaffer, Michael ;

Balasubramanian, Sriram ;

Vermeulen, Jessica ;

Cheson, Bruce D. ;

Salles, Gilles .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) :2405-+

[30] Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer [J].

Kwon, Minsuk ;

Kim, Gahyun ;

Kim, Ryul ;

Kim, Kyu-Tae ;

Kim, Seung Tae ;

Smith, Simon ;

Mortimer, Peter G. S. ;

Hong, Jung Yong ;

Loembe, Arsene-Bienvenu ;

Irurzun-Arana, Itziar ;

Koulai, Loumpiana ;

Kim, Kyoung-Mee ;

Kang, Won Ki ;

Dean, Emma ;

Park, Woong-Yang ;

Lee, Jeeyun .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)

← 1 2 3 4 5 →